InflaRx (IFRX) announced that the World Health Organization has granted the international nonproprietary, or generic, name of “izicopan” to the company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO’s Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances. In the next step of this process, the name “izicopan” will be published in the recommended list of INNs.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx downgraded to Market Perform from Outperform at Leerink
- Largest borrow rate increases among liquid names
- Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
- InflaRx price target raised to $8 from $3 at Cantor Fitzgerald
- InflaRx price target raised to $9 from $2 at Raymond James